Canada markets closed
  • S&P/TSX

    17,845.91
    -70.29 (-0.39%)
     
  • S&P 500

    3,841.47
    -11.60 (-0.30%)
     
  • DOW

    30,996.98
    -179.03 (-0.57%)
     
  • CAD/USD

    0.7852
    -0.0062 (-0.78%)
     
  • CRUDE OIL

    51.98
    -1.15 (-2.16%)
     
  • BTC-CAD

    41,017.05
    -569.71 (-1.37%)
     
  • CMC Crypto 200

    651.44
    +41.45 (+6.79%)
     
  • GOLD FUTURES

    1,855.50
    -10.40 (-0.56%)
     
  • RUSSELL 2000

    2,168.76
    +27.34 (+1.28%)
     
  • 10-Yr Bond

    1.0910
    -0.0180 (-1.62%)
     
  • NASDAQ

    13,543.06
    +12.15 (+0.09%)
     
  • VOLATILITY

    21.91
    +0.59 (+2.77%)
     
  • FTSE

    6,695.07
    -20.35 (-0.30%)
     
  • NIKKEI 225

    28,631.45
    -125.41 (-0.44%)
     
  • CAD/EUR

    0.6447
    -0.0053 (-0.82%)
     

Dynavax to Report Second Quarter 2020 Financial Results and Host Conference Call on August 6, 2020

Dynavax Technologies Corporation
·1 min read

EMERYVILLE, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report second quarter 2020 financial results on Thursday, August 6, 2020, after the U.S. financial markets close.

Dynavax will host a conference call and live audio webcast on Thursday, August 6, 2020 at 4:30 p.m. (ET)/1:30 p.m. (PT).

The live audio webcast may be accessed through the “Events & Presentations” page on the “Investors” section of the Company’s website at www.dynavax.com. Alternatively, participants may dial (866) 420-4066 (domestic) or (409) 217-8237 (international) and refer to conference ID 8187870. A replay of the webcast will be available for 30 days following the live event.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company launched its first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], in February 2018, following U.S. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:
Nicole Arndt, Senior Manager, Investor Relations
narndt@dynavax.com
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com